141 related articles for article (PubMed ID: 8611049)
21. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.
Faivre S; Djelloul S; Raymond E
Semin Oncol; 2006 Aug; 33(4):407-20. PubMed ID: 16890796
[TBL] [Abstract][Full Text] [Related]
22. How to develop a successful cancer drug--molecules to medicines or targets to treatments?
Newell DR
Eur J Cancer; 2005 Mar; 41(5):676-82. PubMed ID: 15763642
[TBL] [Abstract][Full Text] [Related]
23. Improving the evaluation of new cancer treatments: challenges and opportunities.
Rothenberg ML; Carbone DP; Johnson DH
Nat Rev Cancer; 2003 Apr; 3(4):303-9. PubMed ID: 12671669
[TBL] [Abstract][Full Text] [Related]
24. Cancer Drug Development: New Targets for Cancer Treatment.
Curt GA
Oncologist; 1996; 1(3):II-III. PubMed ID: 10387987
[TBL] [Abstract][Full Text] [Related]
25. [Target selectivity of anticancer drugs].
Fattoruso SI; Di Lauro L; Conti F; Amodio A; Lopez M
Clin Ter; 2008; 159(3):189-206. PubMed ID: 18594750
[TBL] [Abstract][Full Text] [Related]
26. [Problems of tumor progression: doubts or hopes at the turn of the Millennium?].
Tímár J
Orv Hetil; 2000 Apr; 141(17):891-9. PubMed ID: 10827469
[TBL] [Abstract][Full Text] [Related]
27. Targeted cancer therapy: conferring specificity to cytotoxic drugs.
Chari RV
Acc Chem Res; 2008 Jan; 41(1):98-107. PubMed ID: 17705444
[TBL] [Abstract][Full Text] [Related]
28. Polyamines and cancer: old molecules, new understanding.
Gerner EW; Meyskens FL
Nat Rev Cancer; 2004 Oct; 4(10):781-92. PubMed ID: 15510159
[TBL] [Abstract][Full Text] [Related]
29. Improving the design of phase II trials of cytostatic anticancer agents.
Stone A; Wheeler C; Barge A
Contemp Clin Trials; 2007 Feb; 28(2):138-45. PubMed ID: 16843736
[TBL] [Abstract][Full Text] [Related]
30. [New guidelines to evaluate the response to treatment in solid tumors].
Duffaud F; Therasse P
Bull Cancer; 2000 Dec; 87(12):881-6. PubMed ID: 11174117
[TBL] [Abstract][Full Text] [Related]
31. [Front-line drug discovery system for cancer].
Mizukami T
Gan To Kagaku Ryoho; 2008 Dec; 35(13):2293-300. PubMed ID: 19098393
[TBL] [Abstract][Full Text] [Related]
32. [New trends in assessment in anticancer treatments by phase II clinical trials].
Medioni JR; Rycke YD; Asselain B
Bull Cancer; 2000 Jul; 87(7-8):551-6. PubMed ID: 10969213
[TBL] [Abstract][Full Text] [Related]
33. Cancer chemopreventive agents-drugs for the 21st century?
Baer-Dubowska W
Acta Pol Pharm; 2006; 63(5):369-73. PubMed ID: 17357586
[TBL] [Abstract][Full Text] [Related]
34. Importance of molecular computer modeling in anticancer drug development.
Geromichalos GD
J BUON; 2007 Sep; 12 Suppl 1():S101-18. PubMed ID: 17935268
[TBL] [Abstract][Full Text] [Related]
35. [Basic rules and problems of phase study of new anticancer agents].
Saito T
Gan To Kagaku Ryoho; 1984 Mar; 11(3):377-82. PubMed ID: 6703716
[TBL] [Abstract][Full Text] [Related]
36. Targeting oncogenes and tumor suppressors genes to mitigate chemoresistance.
Fatemian T; Chowdhury EH
Curr Cancer Drug Targets; 2014; 14(7):599-609. PubMed ID: 25308718
[TBL] [Abstract][Full Text] [Related]
37. [Current emphasis in experimental cancer research and its relation to clinical oncology].
Seeber S
Onkologie; 1986 Oct; 9 Suppl 2():14, 17-9. PubMed ID: 3534669
[No Abstract] [Full Text] [Related]
38. [Main problems of the method of clinical study of new antineoplastic agents].
Astrakhan VI
Vestn Akad Med Nauk SSSR; 1966; 21(4):85-92. PubMed ID: 4882836
[No Abstract] [Full Text] [Related]
39. Signalling pathways as targets for anticancer drug development.
Powis G
Pharmacol Ther; 1994; 62(1-2):57-95. PubMed ID: 7991648
[TBL] [Abstract][Full Text] [Related]
40. [The introduction of new drugs from the basic research to clinical application--issues in the drug development].
Watanabe T; Saijo N
Gan To Kagaku Ryoho; 1994 Oct; 21 Suppl 3():289-91. PubMed ID: 7986105
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
